Schadendorf D - Search Results

1

Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma.

Rothfels H, Paschen A, Schadendorf D. Rothfels H, et al. Among authors: schadendorf d. Exp Dermatol. 2003 Dec;12(6):799-810. doi: 10.1111/j.0906-6705.2003.00093.x. Exp Dermatol. 2003. PMID: 14714561

2

Expression of growth factor receptors on human melanoma cells: comparison of modulating effects of interferons and retinoids.

Worm M, Reichert U, Dippel E, Czarnetzki BM, Schadendorf D. Worm M, et al. Among authors: schadendorf d. Exp Dermatol. 1993 Oct;2(5):217-23. doi: 10.1111/j.1600-0625.1993.tb00036.x. Exp Dermatol. 1993. PMID: 7512881

3

Differential promoter activity in benign and malignant human cells of skin origin.

Artuc M, Nürnberg W, Platzer M, Czarnetzki BM, Schadendorf D. Artuc M, et al. Among authors: schadendorf d. Exp Dermatol. 1995 Oct;4(5):317-21. doi: 10.1111/j.1600-0625.1995.tb00212.x. Exp Dermatol. 1995. PMID: 8589924

4

Cell-based vaccination against melanoma--background, preliminary results, and perspective.

Sun Y, Paschen A, Schadendorf D. Sun Y, et al. Among authors: schadendorf d. J Mol Med (Berl). 1999 Aug;77(8):593-608. doi: 10.1007/s001099900039. J Mol Med (Berl). 1999. PMID: 10543391 Review.

5

Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.

Sun Y, Song M, Stevanović S, Jankowiak C, Paschen A, Rammensee HG, Schadendorf D. Sun Y, et al. Among authors: schadendorf d. Int J Cancer. 2000 Aug 1;87(3):399-404. doi: 10.1002/1097-0215(20000801)87:3<399::aid-ijc14>3.0.co;2-9. Int J Cancer. 2000. PMID: 10897046

6

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma.

Schadendorf D, Paschen A, Sun Y. Schadendorf D, et al. Immunol Lett. 2000 Sep 15;74(1):67-74. doi: 10.1016/s0165-2478(00)00251-0. Immunol Lett. 2000. PMID: 10996630 Review.

7

Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity.

Paschen A, Dittmar KE, Grenningloh R, Rohde M, Schadendorf D, Domann E, Chakraborty T, Weiss S. Paschen A, et al. Among authors: schadendorf d. Eur J Immunol. 2000 Dec;30(12):3447-56. doi: 10.1002/1521-4141(2000012)30:12<3447::AID-IMMU3447>3.0.CO;2-M. Eur J Immunol. 2000. PMID: 11093163 Free article.

8

Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.

Sun Y, Sijts AJ, Song M, Janek K, Nussbaum AK, Kral S, Schirle M, Stevanovic S, Paschen A, Schild H, Kloetzel PM, Schadendorf D. Sun Y, et al. Among authors: schadendorf d. Cancer Res. 2002 May 15;62(10):2875-82. Cancer Res. 2002. PMID: 12019167

9

Gene-based therapy of malignant melanoma.

Schadendorf D. Schadendorf D. Semin Oncol. 2002 Oct;29(5):503-12. doi: 10.1053/sonc.2002.35245. Semin Oncol. 2002. PMID: 12407515 Review.

10

Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events.

Paschen A, Méndez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, Garrido F, Schadendorf D. Paschen A, et al. Among authors: schadendorf d. Int J Cancer. 2003 Mar 1;103(6):759-67. doi: 10.1002/ijc.10906. Int J Cancer. 2003. PMID: 12516095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,106 results

Search Page

Filters